New brain scan could spot inflammation in Parkinson's
NCT ID NCT04062526
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This early-phase study tests whether a new type of PET scan can measure inflammation in the brains of people with Parkinson's disease. Researchers will compare scans from 11 participants (both with Parkinson's and healthy volunteers) to see if the imaging drug 18F-NOS can help diagnose or track the disease. The goal is to understand how inflammation relates to Parkinson's, not to provide a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
11 people
The number who actually took part.
- Started
-
Aug 2019
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria (HC and PD cohorts) 1. Participants will be 18-75 years of age. 2. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. 3. Subjects with known neuropsychiatric disorder may be eligible if, in the opinion of an investigator, the psychiatric condition would not compromise subject safety or successful participation in the study. Inclusion Criteria (PD cohort only) 1. History of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria(1) per neurologist review. 2. Diagnosed with Parkinson's Disease at least 3 year prior to enrollment. 3. Subjects will be selected who have the capacity to give their own informed consent, in the opinion of a neurology investigator. Exclusion Criteria (HC and PD cohorts) 1. Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child- bearing potential within one day of the PET/CT scan. 2. At screening, the participant's weight is \> 350 lb. 3. Subject reported claustrophobia that in the opinion of an investigator would interfere with acquisition of the structural MRI required for PET co-registration, and/or the PET scan itself. 4. History of epilepsy or seizure disorder as assessed by medical record review and/or self-report. 5. History of head trauma that in the opinion of an investigator may interfere with the uptake of applicable radiotracer as assessed by medical record review and/or self- report. 6. Current tobacco or nicotine dependence. History of greater than 5 pack years of smoking and less than 2 years since smoking cessation. 7. Self-reported current alcohol consumption of greater than or equal to 25 drinks per week. 8. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician. 9. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study. Exclusion Criteria (HC cohort only) 1. History of first degree relative with Parkinson's Disease. 2. Use of a CNS drug (prescription, over-the counter or recreational) within 30 days of screening, as assessed by review of medical history and concomitant medication review at screening (from medical record and/or self-report) that are deemed by a physician or investigator to have a potential influence on the binding of the applicable radiotracer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Individualized 130 hz subthalamic temporal interference stimulation versus medication for motor symptoms in parkinson disease
- A pharmacokinetic study of NTI164 in healthy adult volunteers
- Parkinson's improvement activated by hula understanding (PAHU) - part 2
- Half a million people join quest to decode Parkinson's risk
- Can a new injection SGB-9768 pass its first safety test?
- Can a diabetes drug slow Parkinson's? a trial puts it to the test